Synthesis and therapeutic evaluation of an aptide–docetaxel conjugate targeting tumor-associated fibronectin
Authors:
- 1 March 2014
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 178, 118-124
Abstract
No abstract availableKeywords
Funding Information
- Radiation Technology R&D program (2012035409)
- Global Research Laboratory (2012045436)
This publication has 36 references indexed in Scilit:
- Challenges in design and characterization of ligand-targeted drug delivery systemsJournal of Controlled Release, 2012
- Development of a Peptide–Drug Conjugate for Prostate Cancer TherapyMolecular Pharmaceutics, 2011
- Biological evaluation of Paclitaxel-peptide conjugates as a model for MMP2-targeted drug deliveryCancer Biology & Therapy, 2010
- Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted ChemotherapyJournal of Medicinal Chemistry, 2009
- Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing LigandMolecular Pharmaceutics, 2009
- Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2British Journal of Pharmacology, 2008
- Arming antibodies: prospects and challenges for immunoconjugatesNature Biotechnology, 2005
- Recent advances in tumor-targeting anticancer drug conjugatesBioorganic & Medicinal Chemistry, 2005
- Synthesis and Biological Evaluation of Paclitaxel−C225 Conjugate as a Model for Targeted Drug Delivery1Bioconjugate Chemistry, 2003
- Targeted prodrug treatment of HER‐2‐positive breast tumor cells using trastuzumab and paclitaxel linked by A‐Z‐CINNTM LinkerJournal of Experimental Therapeutics and Oncology, 2003